SCHEMBL29537

SCHEMBL29537

NC(=O)c1cc2ccccc2[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.58
DDO Q99489 1/20 0.58
SMYD3 Q9H7B4 2/20 0.55
BRD4 O60885 1/20 0.53
PADI4 Q9UM07 2/20 0.50
CHEK1 O14757 1/20 0.50
KDR P35968 1/20 0.50
FLT3 P36888 1/20 0.50
KDM4E B2RXH2 6/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MAPT P10636 1/20 0.49
SRD5A2 P31213 1/20 0.49
MAPK1 P28482 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390425 1.00 DAO (0.58) DAODDOSMYD3BRD4PADI4
Hydrochloric Acid SCHEMBL30321479 0.98 DAO (0.56) DAODDOSMYD3BRD4PADI4
Pyrrole SCHEMBL6891936 0.92 DAO (0.50) DAODDOSMYD3BRD4PADI4
SCHEMBL1367711 0.85 DAO (0.61) DAODDOSMYD3BRD4PADI4
SCHEMBL19144385 0.84 DAO (0.56) DAODDOSMYD3BRD4PADI4
SCHEMBL5469228 0.84 DAO (0.56) DAODDOSMYD3BRD4PADI4
SCHEMBL31394 0.84 KDM4E (0.59) DAODDOSMYD3BRD4PADI4
SCHEMBL29364659 0.84 KDM4E (0.59) DAODDOSMYD3BRD4PADI4
SCHEMBL16627746 0.82 DAO (0.58) DAODDOSMYD3BRD4PADI4
Hydrochloric Acid SCHEMBL5027809 0.82 KDM4E (0.58) DAODDOSMYD3BRD4PADI4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-07 US claimed
EP-2609083-B1 SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUENENTHAL GMBH (DE) 2015-02-25 EP claimed
EP-2627638-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. Immunahr AB (SE) 2013-08-21 EP claimed
EP-2507225-A1 L -DIHYDRO-2-OXOQUINOLINE COMPOUNDS A 5-HT4 RECEPTOR LIGANDS Suven Life Sciences Limited (IN) 2012-10-10 EP claimed
WO-2012050500-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. PETTERSSON LARS (SE) 2012-04-19 WO claimed
WO-2011030349-A1 L -DIHYDRO-2-OXOQUINOLINE COMPOUNDS A 5-HT4 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2011-03-17 WO claimed
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-07 US disclosed
CN-121574131-A Heterocyclic compounds for insect repellent 勃林格殷格翰动物保健有限公司 2026-02-27 CN disclosed
US-12559503-B2 Anthelmintic aza-benzothiophene and aza-benzofuran compounds BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2026-02-24 US disclosed
EP-4661870-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS Bayer Aktiengesellschaft (DE) 2025-12-17 EP disclosed
EP-4582448-A2 S100 PROTEINS AS NOVEL THERAPEUTIC TARGETS IN MYELOPROLIFERATIVE NEOPLASMS Erasmus University Rotterdam Medical Center (NL) 2025-07-09 EP disclosed
US-12312356-B2 Anthelmintic heterocyclic compounds BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2025-05-27 US disclosed
EP-4185292-B1 S100 PROTEINS AS NOVEL THERAPEUTIC TARGETS IN MYELOPROLIFERATIVE NEOPLASMS UNIV ERASMUS MED CT ROTTERDAM (NL) 2025-05-21 EP disclosed
US-5622967-A NERVOUS SYSTEM DISORDERS STERLING WINTHROP, INC. (US) 1997-04-22 US disclosed
WO-1997004775-A1 QUINOLONES AND THEIR THERAPEUTIC USE CHIROSCIENCE LIMITED (GB) 1997-02-13 WO disclosed
WO-1997004775-A1 QUINOLONES AND THEIR THERAPEUTIC USE CHIROSCIENCE LIMITED (GB) 1997-02-13 WO disclosed
WO-1997004779-A1 QUINOLONES AND THEIR THERAPEUTIC USE CHIROSCIENCE LIMITED (GB) 1997-02-13 WO disclosed
EP-0446604-A2 Pyridine and related aza heterocycle derivatives as cardiovascular agents AMERICAN CYANAMID COMPANY (US) 1991-09-18 EP disclosed
US-4959363-A HERPES VIRUS STERLING DRUG INC. (US) 1990-09-25 US disclosed
US-4284768-A 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS ZC3HAV1, CCR1, CCR6 DAO 1055/4885DDO 1595/4885SMYD3 957/4885
US-12312356-B2 Anthelmintic heterocyclic compounds AADAC, HNMT, HRH4 DAO 1165/4885DDO 1816/4885SMYD3 237/4885
US-12559503-B2 Anthelmintic aza-benzothiophene and aza-benzofuran compounds HDAC5, NR5A2, HRH4 DAO 287/4885DDO 437/4885SMYD3 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.